---
title: "Vertex Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-11 06:38:07"
summary: "Vertex Pharmaceuticals Inc reported quarterly adjusted earnings of $3.98​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $4.20. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.03 per share. Wall Street..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Vertex Pharmaceuticals Inc reported quarterly adjusted earnings of $3.98​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $4.20. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.03 per share. Wall Street expected results to range from $3.41 to $4.85 per share.
* Revenue rose 15.7% to $2.91 billion from a year ago; analysts expected $2.78 billion.
* Vertex Pharmaceuticals Inc's reported EPS for the quarter was $3.50​.
* The company reported quarterly net income of $913 million.
* Vertex Pharmaceuticals Inc shares had risen by 16.5% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 1.8% in the last three months.​
* In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 11 "hold" and 2 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $520.00

This summary was machine generated from LSEG data February 10 at 10:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | 4.03 | 3.98 | Missed |
| Sep. 30 2024 | 4.14 | 4.38 | Beat |
| Jun. 30 2024 | 2.94 | -12.83 | Missed |
| Mar. 31 2024 | 4.06 | 4.76 | Beat |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P12FH:0-vertex-pharmaceuticals-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
